ArticleInfluenza and other respiratory viruses2026
Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09-Associated Hospitalizations With SARI in Beijing, China, in the 2024-2025 Season.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundIn the 2024-2025 season, influenza activity returned to pre-COVID-19 pandemic levels, with A(H1N1)pdm09 as the predominant subtype. Reassessment vaccine effectiveness (VE) in hospitalized patients is critical to inform potential adjustments to vaccination policy.
methodsUsing a test-negative design, we evaluated the VE of the seasonal influenza vaccine during the 2024-2025 season against A(H1N1)pdm09-associated hospitalizations with severe acute respiratory infections (SARI) in Beijing, China, from December 9, 2024 to February 9, 2025. VE was estimated by comparing the odds of influenza vaccination between case-patients (those testing positive for A(H1N1)pdm09) and controls (influenza test-negative patients), applying inverse-propensity-to-be-vaccinated weights.
resultsThe analysis included 1608 hospitalized SARI patients (17.4% tested positive for A(H1N1)pdm09; 13.8% were vaccinated overall). The adjusted VE against A(H1N1)pdm09-associated hospitalizations was 18.8% (95% CI: 0.9% to 33.6%) overall. Specifically, the VE was 45.4% (95% CI: 10.0% to 67.1%) in children aged 0.5-17 years, 43.8% (95% CI: -20.8% to 76.1%) in adults aged 18-59 years, and 8.6% (95% CI: -15.8% to 27.9%) in older adults ≥ 60 years. Among individuals with chronic conditions, the VE was 18.5% (95% CI: -2.3% to 35.2%) and was higher among those with chronic respiratory conditions (40.6%, 95% CI: -1.7% to 65.7%).
conclusionsDuring the 2024-2025 season in Beijing, the overall VE against A(H1N1)pdm09-associated SARI hospitalizations was suboptimal. However, moderate VE was observed among children and younger adults, while limited effectiveness was seen in the elderly. Optimizing influenza vaccination strategies, including the introduction of high-dose or adjuvanted vaccines to enhance immune response in older adults, is crucial to alleviate influenza-associated hospitalizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.